Evidence map›Paper›PMID 42294559›Full record

ReviewMedicinal research reviews2026

Small-Molecule Kinase Inhibitors Modulating Circadian Rhythms.

Irene Castellino, Manuela Bartolini, Rudolf Andrys, Kamil Musilek

Abstract readReview
In one paragraph

Review in Medicinal research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Irene CastellinoDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.ORCID https://orcid.org/0009-0007-4683-9046
Manuela BartoliniDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0002-2890-3856
Rudolf AndrysDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.ORCID https://orcid.org/0000-0003-1108-3924
Kamil MusilekDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.ORCID https://orcid.org/0000-0002-7504-4062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The circadian clock mechanism generates 24-h rhythms crucial for regulating various physiological processes, and its dysregulation has been implicated in numerous diseases. In cells, the circadian clock operates through a transcriptional-translational feedback loop, where phosphorylation plays a pivotal role in maintaining accurate circadian rhythms. Consequently, kinase inhibitors have emerged as promising targets for modulating the circadian clock and potentially treating circadian-related diseases. This review aims to provide an overview of the current state-of-the-art of kinase inhibitors with effects on the mammalian circadian clock. By highlighting promising targets and addressing the limitations of existing inhibitors, this review intends to provide a guide for future research efforts towards the development of novel compounds for the treatment of circadian-related disorders. Furthermore, it highlights the critical discrepancy between in vitro activity and in vivo effectiveness, emphasizing the critical need for rigorous in vivo validation to translate the therapeutic potential of kinase inhibitors into effective treatments for these disorders.

Indexed as

Circadian RhythmProtein Kinase InhibitorsSmall Molecule LibrariesAnimalsCircadian ClocksHumansProtein Kinase InhibitorsSmall Molecule Librariescircadian clockcircadian rhythminhibitorkinase

Identifiers

PMID42294559
PMCPMC13637069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.